Idorsia Pharmaceuticals Ltd company information, Employees & Contact Information

Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability GlobeNewswire

Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds Yahoo Finance

Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN - a US initiative to transform care for patients with difficult-to-control hypertension PR Newswire

Idorsia launches an offering of registered shares – to fund the company to overall profitability GlobeNewswire

Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement Yahoo Finance

Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results Yahoo Finance

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025 Yahoo! Finance UK

Invitation to Idorsia’s aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call GlobeNewswire

Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China GlobeNewswire

Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025 GlobeNewswire

Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025 GlobeNewswire

Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension GlobeNewswire

TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product” GlobeNewswire

Idorsia furthers the science of sleep and insomnia at World Sleep 2025 GlobeNewswire

Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia GlobeNewswire

Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations Yahoo Finance

A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans GlobeNewswire

Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension GlobeNewswire

Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders Yahoo Finance

Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia GlobeNewswire

Idorsia announces financial results for 2024 GlobeNewswire

Idorsia and Viatris update their collaboration for selatogrel and cenerimod GlobeNewswire

Idorsia and Viatris enter into a significant global research and development collaboration Yahoo Finance

Idorsia announces changes to Idorsia Executive Committee and Board of Directors Yahoo Finance

Large-Scale Synthesis of LPA1-Receptor Antagonist ACT-1016-0707 ACS Publications

Idorsia announces financial results for the first nine months of 2024 GlobeNewswire

Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million Yahoo Finance

New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024 Yahoo! Finance UK

FDA Approves Aprocitentan (Tryvio) for Treatment-Resistant Hypertension HCPLive

Tausif ('Tosh') Butt to Join Idorsia Pharmaceuticals U.S. as President and General Manager PR Newswire

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond GlobeNewswire

Idorsia’s novel treatment for chronic insomnia wins the GlobeNewswire

Idorsia presents at the 41st J.P. Morgan Healthcare Conference – Achievements in 2022 provide the foundation for our success in 2023 Yahoo! Finance UK

receptor) antagonist: Tolerability, pharmacokinetics and target engagement British Pharmacological Society | Journals

Idorsia launches QUVIVIQ (daridorexant) in Switzerland – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning Yahoo! Finance UK

Idorsia Files Petition with the Drug Enforcement Administration (DEA) Urging Them to De-Schedule Dual Orexin Receptor Antagonist Class of Insomnia Medications PR Newswire

Idorsia Announces its Insomnia Medication, QUVIVIQ (daridorexant), is now Covered by TRICARE PR Newswire

Idorsia U.S. Announces First Wave of Patients Prescribed QUVIVIQ (daridorexant) through Partnership with Pharmacy Services Provider PR Newswire

Idorsia secures additional cash by entering into a building sale and leaseback agreement GlobeNewswire